AbangeLabsSweden reimbursed Litfulo for severe alopecia areata after cost-utility review, another concrete HTA signal for evidence and access teams. https://www.mattheneus.com/editorial/tlv-litfulo-ritlecitinib-alopecia-areata-reimbursement-allegro-cost-utility-2026-05-26 #HTA #HealthEconomics #Pharma
Sweden reimburses Litfulo for severe alopecia areata after ALLEGRO cost-utility review
Sweden's Dental and Pharmaceutical Benefits Agency (TLV) decided that Litfulo, ritlecitinib, will enter the high-cost protection scheme for severe alopecia areata from 1 June 2026. The health technology assessment (HTA) basis is ALLEGRO 2b/3, a placebo-controlled randomised controlled trial, plus a Markov cost-utility model against no add-on to best supportive care.